-
Posted by
Two Blokes Apr 19 -
Filed in
Stock
-
21 views
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the management's ability to reiterate its ambitious FY2025 guidance, despite the supposed hundreds of millions in tariff impact. Combined with the richer Free Cash Flow generation, healthier balance sheet, and high single-digits dividend per share growth, we believe that ABT remains well positioned to outperform ahead.
